Director: António Medina Almeida
The hematology session at the Leaping Forward congress will explore the impact that new molecular biology technology has had on the diagnosis, prognosis and treatment of patients with hematological malignancies. The technical aspects of novel DNA sequencing technologies will be explained in detail, exploring their advantages and pitfalls. This will be followed by in depth assesment of the impact of novel mutations in the diagnosis and risk stratification of lymphoid and myeloid malignancies, indicating how these findings have brought important insights into the pathophysiology of these diseases. The most impactful final note will be reserved to explore how these novel findings have led to the development and use of new targeted therapies for these important oncological diseases.